Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Harvard Bioscience's Revenue for the
three
months ended in Jun. 2026 was €19.73 Mil. Harvard Bioscience's average Accounts Receivable for the
three
months ended in Jun. 2026 was €12.60 Mil.
Hence, Harvard Bioscience's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.57.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Harvard Bioscience Receivables Turnover Related Terms
Harvard Bioscience Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a Receivables Turnover of 1.57 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #328 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is Harvard Bioscience's Receivables Turnover too high?
Harvard Bioscience's current Receivables Turnover is 1.57. The Medical Devices & Instruments industry median Receivables Turnover is 5.61. Harvard Bioscience's value of 1.57 is 72% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #328 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Receivables Turnover compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #328 out of 811 companies for Receivables Turnover. This puts Harvard Bioscience in the upper half of its industry. The industry median Receivables Turnover is 5.61. Harvard Bioscience's value of 1.57 is 72% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.61, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Receivables Turnover of 1.57 is 72% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Receivables Turnover is 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Receivables Turnover of 1.57. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Receivables Turnover is 1.57 and 72% below the Medical Devices & Instruments industry median of 5.61. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Receivables Turnover is 1.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
Receivables Turnover: 1.57
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 72% below the Medical Devices & Instruments median (#328 of 811)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
